Safinamide: an add-on treatment for managing Parkinson’s disease
Thomas Müller Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, Germany Abstract: Heterogeneous expression of neurotransmitter deficits results from onset and progression of Parkinson’s disease. Intervals, characterized by reappearance of motor and associated certain nonmotor sy...
Saved in:
Main Author: | Müller T (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Current Evidence for the Use of Safinamide for the Treatment of Parkinson’s Disease
by: Abbruzzese G, et al.
Published: (2021) -
Investigational agents in the treatment of Parkinson's disease: focus on safinamide
by: Malek NM, et al.
Published: (2012) -
Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
by: Stocchi F, et al.
Published: (2016) -
Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
by: Müller T
Published: (2016) -
Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
by: Bette S, et al.
Published: (2018)